752242-66-3

Upstream product

• 752242-65-2 3-(6-ethanesulfonylpyridin-3-yloxy)-5-hydroxybenzoic acid methyl ester 
• 1137917-19-1 C₁₀H₂₄O₄SSi 
• 859536-33-7 5-chloro-2-ethanesulfonyl-pyridine 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 136918-07-5 (2R)-1[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-propanol 

Downstream Products

• 1137917-12-4 bis[3-(6-ethanesulfonylpyridin-3-yloxy)-5-((S)-2-hydroxy-1-methylethoxy)benzoic acid] 1,4-diazabicyclo[2.2.2]octane salt 
• 1309086-32-5 C₁₈H₂₁NO₇S 
• 1137916-97-2 3-(6-ethanesulfonylpyridin-3-yloxy)-5-((S)-2-hydroxy-1-methylethoxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide methanesulfonic acid salt 

Relevant academic research and scientific papers

A large-scale synthesis of potent glucokinase activator MK-0941 via selective o -arylation and o -alkylation

An efficient, practical preparation of MK-0941, a potent glucokinase activator, is described. Keys to the success of the synthesis are a highly selective mono-O-arylation of methyl 3,5-dihydroxybenzoate with 2-ethanesulfonyl-5-chloropyridine and the choic

HETEROARYLCARBAMOYLBENZENE DERIVATIVE

Compounds having glucokinase activating effects and being useful as treatments for diabetes, which are represented by the following formula (I): [wherein X1 represents oxygen, etc., X2 represents oxygen, etc., R1 represents a group on Ring A such as alkylsulfonyl, etc., R2 represents C3-7 cyclic alkyl optionally substituted with a halogen, etc., R3 represents a substituent on Ring B such as lower alkyl, etc., formula (II): represents 6- to 10-membered aryl, etc., and formula (III): represents monocyclic or bicyclic heteroaryl optionally having on Ring B a substituent represented by R3 above, wherein the carbon atom of Ring B which is bonded to the nitrogen atom of the amide group of formula (I) forms a C=N bond with the nitrogen atom of the ring], as well as their pharmaceutically acceptable salts.